North America Glycobiology Market

North America Glycobiology Market Size (2023 to 2028)

As per the research report, the size of the North America Glycobiology Market was valued at USD 283.11 million in 2023 and is estimated to be growing at a CAGR of 13.3% to reach USD 528.58 million by 2028 from 2023 to 2028.

The North American Glycobiology market is majorly driven by the increasing prevalence of cancer and diabetes across the region. Furthermore, technological advancements in the healthcare sector support market growth; various procedures, including protein characterizations, are evolving into advanced biochemical and chemical research technologies, such as high-performance liquid chromatography, mass spectrometry, and capillary electrophoresis. These sophisticated procedures provide quick and susceptible results, fuelling market expansion.

The increasing investment & funding by the government and non-government organizations for infrastructure development are encouraging market growth. Glycans are involved in every aspect of life's biochemistry, so proteins and peptides cannot be evaluated without understanding the science of glycan synthesis, structural elucidation, functional property identification, and interaction with biological molecules such as lipids and proteins. The growing awareness about the availability of products to conduct protocols with high specificity and sensitivity is most likely to accelerate market growth. The major biotech and pharmaceutical companies are significantly investing in research and development activities to adopt superior biological products, including glycobiology and proteomics products, which are expected to provide lucrative growth opportunities for market growth. In addition, the increasing demand for treating various life-threatening diseases, such as cancer, influences various research and development activities.

However, the growth is restrained by the high cost of products and the shortage of skilled professionals.

This research report on the North America Glycobiology Market has been segmented and sub-segmented into the following categories.  

By Product:

• Enzymes
• Instruments
• Kits & Reagents

By Application:

• Diagnostic
• Drug Discovery
• Oncology

By End User:

• Academic Research Institutions
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations   

By Country:

• U.S
• Canada
• Rest of North America

Geographically, North America dominated the Glycobiology market, and it is anticipated to register a prominent share during the forecast period. The market growth is attributed to the availability of advanced healthcare infrastructure, high healthcare expenditure, and key market players.

Moreover, better accessibility to refined products, growing applications of glycans, and Favorable reimbursement policies are helping the market grow. Further, emerging countries such as the United States and Canada rapidly contribute to regional market growth.

The U.S Glycobiology Market accounted for the largest share of the market, and it is most likely to continue its growth throughout the forecast period. The presence of many research laboratories, pharmaceutical and biotech companies, and increasing investments in R& D activities propel market growth.

The Canada Glycobiology Market is expected to grow at a considerable share during the forecast period. The incidence of chronic illnesses like diabetes and cancer, the high demand for personalized medicines, and the focus on novel drug development and advanced healthcare sectors are uplifting the market growth.

KEY MARKET PLAYERS

Companies playing a dominant role in the North America Glycobiology Market profiled in this report are Agilent Technologies (U.S.), Bruker Corporation (U.S.), Danaher Corporation (U.S.), Takara Bio, Inc. (Japan), Thermo Fisher Scientific (U.S.), and Waters Corporation (U.S.), New England Biolabs (U.S.), ProZyme, Inc. (U.S.), Shimadzu Corporation (Japan), Merck KGaA (Germany).,